._老虎社区_美港股上老虎

ice1991
2021-11-23

Novartis May Have Buyer(s) For Its Sandoz Unit - Report

According to a German newspaper, Swedish-based investment group EQT and the Struengmann family of Ge

Novartis May Have Buyer(s) For Its Sandoz Unit - Report

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":875528274,"tweetId":"875528274","gmtCreate":1637671730524,"gmtModify":1637671730524,"author":{"id":3558581401862827,"idStr":"3558581401862827","authorId":3558581401862827,"authorIdStr":"3558581401862827","name":"ice1991","avatar":"https://static.tigerbbs.com/ff847f0a64ccaa96b7b1f4ae7cb40ef7","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>.</p></body></html>","htmlText":"<html><head></head><body><p>.</p></body></html>","text":".","highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/875528274","repostId":1136165340,"repostType":4,"repost":{"id":"1136165340","kind":"news","pubTimestamp":1637671478,"share":"https://www.laohu8.com/m/news/1136165340?lang=&edition=full","pubTime":"2021-11-23 20:44","market":"us","language":"en","title":"Novartis May Have Buyer(s) For Its Sandoz Unit - Report","url":"https://stock-news.laohu8.com/highlight/detail?id=1136165340","media":"Benzinga","summary":"According to a German newspaper, Swedish-based investment group EQT and the Struengmann family of Ge","content":"<ul>\n <li>According to a German newspaper, Swedish-based investment group EQT and the Struengmann family of Germany are considering a&nbsp;joint move to purchase&nbsp;the&nbsp;<b>Novartis AG's</b>&nbsp;generics outfit, Sandoz, for $21.6 billion.</li>\n</ul>\n<ul>\n <li>The price would make it the largest pharma deal of the year.</li>\n <li>EQT and the Struengmanns, who provided the investment power behind&nbsp;<b>BioNTech SE</b>, have attracted interest from other private equity investors to join the group, the outlet reported.</li>\n <li>Reuters points out that the Struengmann twins have&nbsp;done business with Novartis in the past, selling a generics maker, Hexal, to the company in 2005.</li>\n <li>Similar divestitures have been made by other pharmaceutical giants designed to focus on the business of developing drugs.</li>\n <li><b>Merck &amp; Co Inc</b>&nbsp;has created&nbsp;<b>Organon &amp; Co</b>.&nbsp;<b>Pfizer Inc</b>&nbsp;merged its generics maker, Upjohn, with&nbsp;<b>Mylan</b>, creating&nbsp;<b>Viatris Inc</b>.</li>\n <li>Most recently,<b>Johnson &amp; Johnson</b>&nbsp;revealed it was establishing a new publicly-traded company to&nbsp;handle its consumer health business.</li>\n <li>Novartis was nearing the sale of a portion of its generics business to Aurobindo of India for $1 billion before the&nbsp;deal fell through after an antitrust review setback&nbsp;with the U.S. Federal Trade Commission.</li>\n <li><b>Price Action:</b>&nbsp;NVS shares are up 0.97% at $82.11 during the premarket session on the last check Tuesday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis May Have Buyer(s) For Its Sandoz Unit - Report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis May Have Buyer(s) For Its Sandoz Unit - Report\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-23 20:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/m-a/21/11/24244480/novartis-may-have-buyer-s-for-its-sandoz-unit-report><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>According to a German newspaper, Swedish-based investment group EQT and the Struengmann family of Germany are considering a joint move to purchase the Novartis AG's generics outfit, Sandoz, for $21.6 ...</p>\n\n<a href=\"https://www.benzinga.com/m-a/21/11/24244480/novartis-may-have-buyer-s-for-its-sandoz-unit-report\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVS":"诺华"},"source_url":"https://www.benzinga.com/m-a/21/11/24244480/novartis-may-have-buyer-s-for-its-sandoz-unit-report","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136165340","content_text":"According to a German newspaper, Swedish-based investment group EQT and the Struengmann family of Germany are considering a joint move to purchase the Novartis AG's generics outfit, Sandoz, for $21.6 billion.\n\n\nThe price would make it the largest pharma deal of the year.\nEQT and the Struengmanns, who provided the investment power behind BioNTech SE, have attracted interest from other private equity investors to join the group, the outlet reported.\nReuters points out that the Struengmann twins have done business with Novartis in the past, selling a generics maker, Hexal, to the company in 2005.\nSimilar divestitures have been made by other pharmaceutical giants designed to focus on the business of developing drugs.\nMerck & Co Inc has created Organon & Co. Pfizer Inc merged its generics maker, Upjohn, with Mylan, creating Viatris Inc.\nMost recently,Johnson & Johnson revealed it was establishing a new publicly-traded company to handle its consumer health business.\nNovartis was nearing the sale of a portion of its generics business to Aurobindo of India for $1 billion before the deal fell through after an antitrust review setback with the U.S. Federal Trade Commission.\nPrice Action: NVS shares are up 0.97% at $82.11 during the premarket session on the last check Tuesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":750,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":1,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}

Novartis May Have Buyer(s) For Its Sandoz Unit - Report

评论（2）

热议股票